Sanofi (NASDAQ: SNY) reported Q2 EPS of EUR1.59. Revenue for the quarter came in at EUR9.99 billion.

GUIDANCE

In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER (before share buyback), now including all expenses from newly acquired businesses4

Sanofi intends to complete its €5 billion share buyback program in 2025. 80.3% has been repurchased to date

For earnings history and earnings-related data on Sanofi (SNY) click here.